Materna Clinic
Mountain View, California, 94040, United States
NCT Number: NCT06397885
To assess the effectiveness of the Milli device in achieving vaginal intercourse
This study is active but is not currently recruiting participants.
18 year and older
Female
Observational
Mountain View, California, 94040, United States
The Milli Vaginal Dilator is a patient-controlled vaginal dilator that provides therapy through distention of the vaginal tissue under electromechanical expansion.
This study is intended to provide data in support of the Milli Vaginal Dilator as a commercially available, over-the-counter medical device.
The Milli has been granted marketing authorization by the FDA under premarket notification K220035 for the following Indications for Use statement:
The Milli Vaginal Dilator is a tool indicated for controlled dilation of the vagina. It can be used for dilation for an examination (by your doctor), in preparation for a surgical procedure, or to help relieve the symptoms of vaginismus (condition that involves tightening of the vaginal muscles) and related painful sex.
.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patient-controlled vaginal dilator that provides therapy through distention of the vaginal tissue under electromechanical expansion
Time frame: 6 months
Ability to achieve full vaginal penetration with the penis of the partner (intercourse) as measured by the Penetration Efficiency Questionnaire (Score of ≥2 on PEQ Question #1) at six months
Time frame: 3 months
Ability to achieve full vaginal penetration with the penis of the partner (intercourse) as
Time frame: 3 months, 6 months
Improvement in ability to achieve vaginal penetration (intercourse and non-intercourse) as measured by a change in baseline in the overall score on the Penetration Efficiency Questionnaire at 3 and 6 months.
Time frame: 3 months, 6 months
Improvement in self-reported sexual function as reported on a change in baseline in the Female Sexual Function Index (FSFI) total score at 3 and 6 months.
Time frame: 3 months, 6 months
Improvement in self-reported pain intensity with intercourse as reported as a change in baseline on a numeric rating scale (NRS) (0= no pain, 10 = worst pain imaginable) at 3 and 6 months
Materna Medical
Industry
Acronym: POMPOM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06840314
Dyspareunia, Female Urogenital Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT00281372
Dyspareunia, Erectile Dysfunction
View Trial DetailsNCT01352546
Dyspareunia, Female Urogenital Diseases
Manchester, New Hampshire, United States
View Trial DetailsNCT06923306
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Vancouver, British Columbia, Canada
View Trial Details